TherapeuticsMD Inc (NYSEMKT:TXMD) has been assigned an average recommendation of “Buy” from the six analysts that are presently covering the stock. One investment analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $13.83.

TXMD has been the topic of a number of research reports. Zacks Investment Research raised shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Saturday, September 3rd. Guggenheim reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Monday, November 7th.

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS Group AG raised its stake in shares of TherapeuticsMD by 2.6% in the first quarter. UBS Group AG now owns 212,878 shares of the specialty pharmaceutical company’s stock worth $1,362,000 after buying an additional 5,455 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in shares of TherapeuticsMD by 10.2% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 3,663,342 shares of the specialty pharmaceutical company’s stock worth $23,445,000 after buying an additional 338,398 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of TherapeuticsMD by 9.2% in the first quarter. BlackRock Fund Advisors now owns 4,682,204 shares of the specialty pharmaceutical company’s stock worth $29,966,000 after buying an additional 392,880 shares in the last quarter. Teachers Advisors Inc. raised its stake in shares of TherapeuticsMD by 19.6% in the first quarter. Teachers Advisors Inc. now owns 225,287 shares of the specialty pharmaceutical company’s stock worth $1,442,000 after buying an additional 36,888 shares in the last quarter. Finally, TIAA CREF Investment Management LLC raised its stake in shares of TherapeuticsMD by 6.2% in the first quarter. TIAA CREF Investment Management LLC now owns 436,911 shares of the specialty pharmaceutical company’s stock worth $2,796,000 after buying an additional 25,596 shares in the last quarter.

TherapeuticsMD (NYSEMKT:TXMD) traded up 1.16% during midday trading on Monday, hitting $6.96. 971,758 shares of the company were exchanged. The firm’s market capitalization is $1.37 billion. The stock has a 50 day moving average of $6.22 and a 200 day moving average of $7.37. TherapeuticsMD has a 1-year low of $4.39 and a 1-year high of $11.26.

TherapeuticsMD (NYSEMKT:TXMD) last announced its quarterly earnings results on Thursday, November 3rd. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by $0.02. The business had revenue of $5.50 million for the quarter, compared to analyst estimates of $5.76 million. The firm’s revenue was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.11) earnings per share. On average, equities analysts predict that TherapeuticsMD will post ($0.46) earnings per share for the current fiscal year.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.